Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results

Creative Commons License

Suha C., Gokhan V. M., Goksal K., Ekrem Y., Mehmet D., Akif O. M.

CARDIOVASCULAR JOURNAL OF AFRICA, cilt.25, sa.4, ss.168-175, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 4
  • Basım Tarihi: 2014
  • Doi Numarası: 10.5830/cvja-2014-036
  • Dergi Adı: CARDIOVASCULAR JOURNAL OF AFRICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.168-175
  • Anahtar Kelimeler: electrocardiography, infliximab, left atrium, rheumatoid arthritis, speckle tracking echocardiography, VENTRICULAR DIASTOLIC DYSFUNCTION, CORONARY-ARTERY-DISEASE, P-WAVE DISPERSION, NECROSIS-FACTOR, INFLAMMATORY MEDIATORS, SUSTAINED IMPROVEMENT, 2-DIMENSIONAL STRAIN, ENDOTHELIAL FUNCTION, HEART-FAILURE, E/A RATIO
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality. In the current prospective study, we addressed the impact of RA on left atrial (LA) function and electrical remodelling. Further, we tried to demonstrate the effects of infliximab, an anti-TNF-alpha agent, on echocardiographical LA abnormality in RA patients with preserved left ventricular (LV) ejection fraction.